Get started

Financials · GH

Guardant Health Inc. (GH) financials

For the twelve months ended Sep 30, 2026, Guardant Health Inc. reported $1.28B of revenue and -$485.07M of net income.

Revenue, TTM
$1.28B
Revenue growth, YoY
+41.7%
Net income, TTM
-$485.07M
Net margin
-37.9%
Free cash flow, TTM
-$232.15M
EPS, diluted, TTM
-$3.69
Cash
$1.03B
Total debt
$1.50B
P/S
15.83
Market cap
$20.25B
Annual revenue$982.02M
FY2016FY2025
Annual net income-$416.28M
FY2016FY2025
Annual free cash flow-$233.07M
FY2016FY2025

GH revenue and earnings growth

GH revenueQ3 2026$360.98M

Quarter YoY
+36.1%
QoQ
+7.8%
FY YoY
+32.9%
5Y CAGR
+27.9%

GH revenue was $360.98M in fiscal Q3 2026 (ended Sep 30, 2026), up 36.1% from a year earlier and up 7.8% from the prior quarter. For the full fiscal 2025 it was $982.02M, up 32.9% from fiscal 2024. Compound annual growth was +27.9% over 5 years. It rose in each of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

GH net incomeQ3 2026-$124.36M

GH net income was -$124.36M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$92.72M a year earlier. For the full fiscal 2025 it was -$416.28M, compared with -$436.37M in fiscal 2024.

GH EPSQ3 2026-$0.93

GH diluted EPS was -$0.93 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.74 a year earlier. For the full fiscal 2025 it was -$3.32, compared with -$3.56 in fiscal 2024.

GH free cash flowQ3 2026-$37.19M

GH free cash flow was -$37.19M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$45.76M a year earlier. For the full fiscal 2025 it was -$233.07M, compared with -$274.94M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$982.02M$739.02M$563.95M$449.54M$373.65M$286.73M$214.38M$90.64M$49.84M$25.25M
Cost of revenue$349.01M$289.80M$227.05M-------
Gross profit$633.01M$449.22M$336.90M-------
Research and development$364.19M$347.75M$367.19M$373.81M$263.22M$149.86M$86.29M$50.71M$25.56M$10.86M
Selling, general and admin$211.41M$180.12M$155.80M$163.96M$206.64M$192.77M$61.40M$36.19M$36.78M$9.92M
Operating income-$437.25M-$443.59M-$564.73M-$544.38M-$411.00M-$254.95M-$82.37M-$92.94M-$76.61M-$43.85M
Interest expense$3.90M$2.58M$2.58M$2.58M$2.58M$4.77M$1.18M$1.25M$2.70M$3.02M
Pre-tax income-$417.54M-$435.09M-$478.76M-$653.45M-$384.47M-$245.90M-$69.72M-$84.22M-$83.21M-$46.13M
Income tax-$1.26M$1.28M$685.0K$1.14M$300.0K$379.0K-$1.87M$38.0K$7.0K$6.0K
Net income-$416.28M-$436.37M-$479.45M-$654.59M-$384.77M-$253.78M-$75.65M-$85.06M-$83.22M-$46.14M
EPS, basic-$3.32-$3.56-$4.28-$6.41-$4.00-$2.60-$0.84-$2.80-$7.07-$3.53
EPS, diluted-$3.32-$3.56-$4.28-$6.41-$4.00-$2.60-$0.84-$2.80-$7.07-$3.53
Diluted shares125.4M122.7M112.0M102.2M101.3M97.5M90.6M30.4M12.6M13.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$378.20M$629.75M$1.13B$141.95M$492.29M$832.98M$143.23M$140.54M$72.60M$33.59M
Short-term investments---$869.58M$440.55M$961.90M$379.57M$278.42M$149.04M-
Receivables$137.85M$110.25M$88.78M$97.26M$97.65M$53.30M$47.99M$35.69M$12.79M-
Inventory$85.88M$71.08M$61.95M$51.60M$30.67M$22.72M$15.18M$9.14M$7.29M-
Current assets$1.47B$1.06B$1.35B$1.19B$1.11B$1.89B$597.36M$468.99M$242.94M-
Goodwill$77.26M$3.29M$3.29M$3.29M$3.29M$3.29M$3.29M$0--
Total assets$2.01B$1.49B$1.79B$1.61B$2.20B$2.27B$962.53M$587.40M$342.94M-
Current liabilities$302.73M$225.58M$205.92M$193.22M$194.69M$66.81M$72.73M$46.94M$19.63M-
Total debt$1.50B$1.14B--------
Total liabilities$2.11B$1.63B$1.63B$1.55B$1.56B$916.19M$114.54M$62.45M$34.33M-
Shareholders' equity-$99.31M-$139.65M$158.68M$60.18M$645.00M$1.30B$798.39M$483.15M$308.61M$79.70M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$184.76M-$239.86M-$324.98M-$309.46M-$209.02M-$103.93M-$47.13M-$72.19M-$72.23M-$36.71M
Capital expenditures$48.31M$35.09M$20.49M$77.46M$75.03M$36.17M$18.72M$20.20M$6.68M$1.77M
Free cash flow-$233.07M-$274.94M-$345.46M-$386.92M-$284.05M-$140.10M-$65.85M-$92.39M-$78.92M-$38.48M
Investing cash flow-$627.20M-$261.31M$840.25M$149.82M-$63.16M-$617.09M-$317.57M-$153.03M-$170.42M$26.20M
Financing cash flow$671.13M-$996.0K$477.38M-$189.09M-$66.82M$1.41B$367.30M$293.16M$281.66M$39.84M
Share repurchases$45.01M$0$0--$0$0$172.0K$7.22M$100.0K
Stock-based compensation$166.22M$140.41M$90.76M$94.69M$151.45M$144.11M$16.95M$6.85M$3.67M$1.97M
Depreciation and amortization$39.74M$42.39M$42.88M$35.96M$22.27M$16.07M$11.41M$7.14M$5.21M$3.69M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY32.9%31.0%25.5%20.3%30.3%33.8%136.5%81.9%97.4%-
Gross margin64.5%60.8%59.7%-------
Operating margin-44.5%-60.0%-100.1%-121.1%-110.0%-88.9%-38.4%-102.5%-153.7%-173.7%
Net margin-42.4%-59.0%-85.0%-145.6%-103.0%-88.5%-35.3%-93.8%-167.0%-182.7%
Free cash flow margin-23.7%-37.2%-61.3%-86.1%-76.0%-48.9%-30.7%-101.9%-158.3%-152.4%
Return on equity---302.1%-1087.7%-59.7%-19.5%-9.5%-17.6%-27.0%-57.9%
Return on assets-20.7%-29.4%-26.8%-40.7%-17.5%-11.2%-7.9%-14.5%-24.3%-
Current ratio4.844.686.546.175.7228.278.219.9912.38-

Source: XBRL data Guardant Health Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

GH peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
GH$1.28B+41.7%-$485.07M-37.9%$20.25B
UNH$449.66B+3.3%$15.88B3.5%$353.17B
ELV$201.83B+3.6%$5.13B2.5%$91.96B
CI$286.32B+6.8%$5.99B2.1%$77.58B
HUM$154.19B+22.0%$1.25B0.8%$52.08B
NTRA$2.91B+37.4%-$164.71M-5.7%$44.78B
CNC$203.90B+9.7%$1.46B0.7%$34.53B
ILMN$4.54B+5.8%$895.00M19.7%$32.22B
LH$14.59B+6.0%$1.00B6.9%$29.77B

GH FAQ

9 questions
  • What is GH revenue?
    Guardant Health Inc. (GH) reported $1.28B of revenue for the twelve months ended Sep 30, 2026. That is up 41.7% from the year before. Revenue for fiscal 2025 was $982.02M.
  • Is GH profitable?
    No. Guardant Health Inc. reported a net loss of $485.07M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does GH have?
    Guardant Health Inc. reported $1.03B in cash and cash equivalents and $1.50B of debt on its most recent balance sheet in SEC filings.
  • How fast is GH revenue growing?
    Guardant Health Inc.'s revenue changed +32.9% in fiscal 2025, to $982.02M. Its compound annual growth rate was +27.9% over 5 years.
  • What is GH gross margin?
    Guardant Health Inc.'s gross profit was $833.70M on $1.28B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 65.2%.
  • What is GH free cash flow?
    Guardant Health Inc. generated -$232.15M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$173.48M less capital expenditures.
  • What is GH earnings per share?
    Diluted earnings per share were -$3.69 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did GH last report financial results?
    The latest statements here come from Guardant Health Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this GH financial data come from?
    Quantisnow builds these statements from the structured XBRL data Guardant Health Inc. files with the SEC. It is provided for information only and is not investment advice.